Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2000 Aug;44(8):2225-9.
doi: 10.1128/AAC.44.8.2225-2229.2000.

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

H W Boucher  1 , C B Wennersten, G M Eliopoulos
Affiliations
Comparative Study

In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria

H W Boucher et al. Antimicrob Agents Chemother. 2000 Aug.

Abstract

The in vitro activities of GAR-936, the 9-t-butylglycylamido derivative of minocycline, were compared with those of doxycycline, minocycline, and tetracycline against 527 gram-positive clinical isolates. GAR-936 inhibited all strains, including those resistant to other tetracyclines, at concentrations of </=2 microg/ml, except two strains of JK diphtheroids for which the MIC was 4 microg/ml.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
MICs (geometric means) of GAR-936 for gram-positive cocci based on resistance (R) or susceptibility (S) to minocycline (Min) or tetracycline (Tet). Among enterococci and staphylococci, susceptible isolates were those for which MICs were ≤4 μg/ml and resistant isolates were those for which MICs were ≥16 μg/ml. Streptococci were grouped according to susceptibility criteria for pneumococci: MICs for susceptible isolates were ≤2 μg/ml, and MICs for resistant isolates were ≥8 μg/ml. Isolates intermediately susceptible to Tet and Min (i.e., enterococci or staphylococci for which MICs were 8 μg/ml and streptococci for which MICs were 4 μg/ml) were included with resistant groups.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin—United States, 1989–1993. Morb Mortal Wkly Rep. 1993;42:597–599. - PubMed
    1. Collins L A, Malanoski G J, Eliopoulos G M, Wennersten C B, Ferraro M J, Moellering R C., Jr In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993;37:598–601. - PMC - PubMed
    1. Edmond M B, Ober J F, Dawson J D, Weinbaum D L, Wenzel R P. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis. 1996;23:1234–1239. - PubMed
    1. Eliopoulos G M, Gardella A, Moellering R C., Jr In vitro activity of Sch 29482 in comparison with other oral antibiotics. J Antimicrob Chemother. 1982;9(Suppl. C):143–152. - PubMed
    1. Eliopoulos G M, Wennersten C B, Cole G, Moellering R C. In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother. 1994;38:534–541. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources